Last reviewed · How we verify
POLIGLUSAM
At a glance
| Generic name | POLIGLUSAM |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy of a Toothpaste in Reducing Plaque, Gingivitis, and Gingival Bleeding (PHASE3)
- Antibiofilm Activity of Chitosan Nanoparticles Against Uropathogenic Escherichia Coli
- Phase 1 Study of VELGRAFT, a Living Cellular Construct, in the Management of Chronic Diabetic Foot Ulcers Which Have Attained Granulation Tissue (PHASE1)
- Directed Topical Drug Delivery for Treatment for PASC Hyposmia (PHASE2)
- Comparing Chitosan Sponge With Hydrocolloid as Dressing for Split-thickness Skin Graft Donor Site Wounds (NA)
- hiPSC-CMs-loaded Chitosan Patch to Treat Severe Chronic Ischemic Heart Disease (PHASE1,PHASE2)
- Evaluating the Efficacy of FoundationDRS Solo in Addition to Standard of Care for the Treatment of Non-healing Diabetic Foot Ulcers (NA)
- "Mulligan Technique vs Phonophoresis With Chitosan for Patellofemoral Pain" (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- POLIGLUSAM CI brief — competitive landscape report
- POLIGLUSAM updates RSS · CI watch RSS